FOXP3 高密度预示生发中心和非生发中心弥漫性大 B 细胞淋巴瘤具有更好的预后。
High density of FOXP3 predicts better prognosis in germinal and non-germinal centre diffuse large B-cell lymphoma.
机构信息
Pathology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Department of Oncologic Pathology, South Egypt Cancer Institute, Faculty of Medicine, Assiut University, Assiut, Egypt.
出版信息
Int J Exp Pathol. 2023 Jun;104(3):128-139. doi: 10.1111/iep.12477. Epub 2023 Mar 28.
Abstract
This study highlights the prognostic impact of FOXP3 and CD68 expression in DLBCL, NOS and in its GCB and non-GCB subtypes. This may help the development of individualized therapy, prognostic prediction and therapy stratification.
摘要
本研究强调了 FOXP3 和 CD68 表达在弥漫性大 B 细胞淋巴瘤、NOS 及其 GCB 和非 GCB 亚型中的预后影响。这可能有助于个体化治疗、预后预测和治疗分层的发展。
相似文献
1
High density of FOXP3 predicts better prognosis in germinal and non-germinal centre diffuse large B-cell lymphoma.FOXP3 高密度预示生发中心和非生发中心弥漫性大 B 细胞淋巴瘤具有更好的预后。
Int J Exp Pathol. 2023 Jun;104(3):128-139. doi: 10.1111/iep.12477. Epub 2023 Mar 28.
2
[Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].CD68、细胞周期蛋白D1的表达及bcl-6基因重排是弥漫性大B细胞淋巴瘤的不良预后因素
Zhonghua Bing Li Xue Za Zhi. 2015 Aug;44(8):559-64.
3
[Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China].[中国上海弥漫性大B细胞淋巴瘤生发中心B细胞样和非生发中心B细胞样类型的患病率]
Zhonghua Bing Li Xue Za Zhi. 2010 May;39(5):313-8.
4
[Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].弥漫性大B细胞淋巴瘤的免疫表型与预后：500例研究
Zhonghua Bing Li Xue Za Zhi. 2011 Apr;40(4):235-9.
5
Intratumoral FOXP3+ Regulatory T Cells in Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤中的肿瘤内FOXP3 +调节性T细胞
Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):534-542. doi: 10.1097/PAI.0000000000000335.
6
MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.MYC易位和拷贝数增加预示成人弥漫性大B细胞淋巴瘤（DLBCL）预后不良，尤其是生发中心样B细胞（GCB）型。
Histopathology. 2008 Aug;53(2):205-17. doi: 10.1111/j.1365-2559.2008.03076.x.
7
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.CD47 表达可预测 Rituximab 联合 CHOP 方案对非生发中心 B 细胞（Non-GCB）弥漫性大 B 细胞淋巴瘤（DLBCL）患者的疗效，但对生发中心 B 细胞（GCB）DLBCL 患者无效。
Cancer Immunol Res. 2019 Oct;7(10):1663-1671. doi: 10.1158/2326-6066.CIR-18-0781. Epub 2019 Aug 13.
8
Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.口腔原发性弥漫性大B细胞淋巴瘤：生发中心分类
Head Neck Pathol. 2010 Sep;4(3):181-91. doi: 10.1007/s12105-010-0184-4. Epub 2010 Jun 9.
9
UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.泛素羧基末端水解酶L1（UCH-L1）在生发中心B细胞中被诱导表达，并可用于识别侵袭性生发中心弥漫性大B细胞淋巴瘤患者。
Blood. 2016 Mar 24;127(12):1564-74. doi: 10.1182/blood-2015-07-656678. Epub 2015 Dec 23.
10
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.在标准化疗基础上加用利妥昔单抗可提高弥漫性大B细胞淋巴瘤生发中心B细胞样和非生发中心B细胞样亚型的生存率。
J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.
本文引用的文献
1
Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study.通过整合中期评估和国际预后指数对弥漫性大B细胞淋巴瘤进行风险分层：一项多中心回顾性研究
Front Oncol. 2021 Dec 16;11:754964. doi: 10.3389/fonc.2021.754964. eCollection 2021.
2
The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.FoxP3+ 调节性 T 细胞和 IDO+ 免疫和肿瘤细胞在恶性黑色素瘤中的作用——免疫组化研究。
BMC Cancer. 2021 May 29;21(1):641. doi: 10.1186/s12885-021-08385-4.
3
Tumor-Associated Macrophages in Tumor Immunity.肿瘤相关巨噬细胞在肿瘤免疫中的作用。
Front Immunol. 2020 Dec 3;11:583084. doi: 10.3389/fimmu.2020.583084. eCollection 2020.
4
Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis.调节性T细胞在淋巴瘤中的预后作用：一项系统评价和荟萃分析。
J Cancer Res Clin Oncol. 2020 Dec;146(12):3123-3135. doi: 10.1007/s00432-020-03398-1. Epub 2020 Sep 29.
5
Inflammatory Cells in Diffuse Large B Cell Lymphoma.弥漫性大B细胞淋巴瘤中的炎症细胞
J Clin Med. 2020 Jul 28;9(8):2418. doi: 10.3390/jcm9082418.
6
Aberrant peripheral blood CD4 CD25 FOXP3 regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma.异常外周血 CD4 CD25 FOXP3 调节性 T 细胞/T 辅助-17 细胞数量与淋巴瘤患者的预后相关。
Cancer Immunol Immunother. 2020 Sep;69(9):1917-1928. doi: 10.1007/s00262-020-02591-y. Epub 2020 May 8.
7
8
Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.弥漫性大 B 细胞淋巴瘤中的肿瘤微环境：作用与预后。
Anal Cell Pathol (Amst). 2019 Dec 16;2019:8586354. doi: 10.1155/2019/8586354. eCollection 2019.
9
Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity.代谢调控 Treg 细胞稳定性、可塑性和组织特异性异质性。
Front Immunol. 2019 Dec 11;10:2716. doi: 10.3389/fimmu.2019.02716. eCollection 2019.
10
Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.肿瘤相关巨噬细胞预测弥漫性大 B 细胞淋巴瘤的预后与外周血绝对单核细胞计数的相关性。
BMC Cancer. 2019 Nov 6;19(1):1049. doi: 10.1186/s12885-019-6208-x.
Zotero 插件